Instalab

Cypress (Cup a 1) IgE Test Blood

Pinpoint cypress pollen as the real driver of your seasonal allergies, beyond what a basic skin test reveals.

Should you take a Cypress (Cup a 1) IgE test?

This test is most useful if any of these apply to you.

Sneezing Through Cypress Season
You have predictable seasonal symptoms in a region with cypress trees and want to know if this pollen is the real driver.
Reacting to Peach or Other Fruits
You have had unexplained or severe fruit reactions and want to check the cypress connection through shared protein families.
Considering Allergy Immunotherapy
You are weighing allergen-specific immunotherapy and need precise information about which pollen to target.
Standard Panel Came Back Clean
Your basic allergy testing was negative but symptoms persist, and you want to check whether cypress was missed.

About Cypress (Cup a 1) IgE

If you live somewhere with cypress trees and you struggle through a predictable misery every winter or early spring, this test answers a specific question: is cypress pollen the actual culprit, or are you reacting to something else entirely? It measures the antibody your body has built against Cup a 1, the dominant allergen in cypress pollen.

This matters because cypress allergy is consistently underdiagnosed when clinicians rely only on broad skin tests or extract-based panels. Knowing whether you are truly sensitized to Cup a 1 can change what you treat, when you treat it, and whether allergen immunotherapy is worth pursuing.

What This Antibody Actually Reflects

Cup a 1 (cypress allergen 1) is a pectate lyase, a plant enzyme that helps pollen grains release their contents. When your immune system mistakes it for a threat, B cells (the antibody-producing cells of your immune system) start manufacturing IgE (immunoglobulin E), a class of antibody that triggers allergic reactions. When you breathe in cypress pollen again, that IgE coats immune cells in your nose, eyes, and airways and tells them to release histamine and other chemicals that cause the classic allergy symptoms.

A positive Cup a 1 IgE result means your immune system has been primed by cypress pollen exposure and is ready to react. A negative or undetectable result strongly argues that cypress is not the main driver of your symptoms, even if you live in a high-exposure region.

Why Cypress Sensitization Is Worth Confirming

Cypress is now recognized as a major sensitizer across Mediterranean Europe and parts of Asia, and Cup a 1 IgE tracks closely with how much cypress pollen you are actually exposed to. In a French multicenter cohort, the odds of being sensitized to Cup a 1 were roughly seven times higher in Montpellier, a high-pollen city, than in Paris. In a Japanese population study of healthy adults, a substantial share had IgE to cypress pollen, making it one of the most common sensitizations identified.

Among allergic children studied across Korea and Japan, cypress sensitization mirrored local pollen counts: regions with heavier exposure produced more sensitization. The pattern is consistent. The amount of cypress in your environment shapes your immune response to it.

Seasonal Allergic Rhinitis and Asthma

Cup a 1 is one of the molecular markers most tightly linked to seasonal allergic rhinitis (hay fever) in cypress-rich regions. In Central Italy, most patients allergic to cypress show strong IgE to Cup a 1. In Southern European multicenter studies, cypress sensitization clusters with moderate-to-severe rhinitis, and many patients are monosensitized, meaning cypress is essentially their only allergen.

Cypress-driven allergy can also coexist with asthma, especially in Mediterranean cohorts where cypress sits alongside grasses and olive as a dominant respiratory sensitizer. Confirming Cup a 1 status helps clarify what is actually fueling your airway symptoms.

The Peach Connection You Might Not Expect

Here is something many people do not realize: cypress pollen allergy can be linked to severe reactions to peach and certain other fruits. The connection runs through a family of proteins called gibberellin-regulated proteins. Cypress contains one called BP14, and peach contains a related protein called Pru p 7. If you make IgE to one, you can react to the other.

In a Spanish pediatric study, sensitization to Pru p 7 was found in a meaningful subset of children with peach allergy and was associated with severe reactions, including anaphylaxis. People who have these reactions typically also show IgE to Cup a 1. If you have unexplained fruit reactions and live in a cypress-exposed region, this is a connection worth investigating.

How It Differs From Cross-Reactive Pollens

Cypress, mountain cedar (Juniperus), and Japanese cedar are botanical cousins, and their major allergens share structural features. Cup a 1 cross-reacts strongly with Jun a 1 (mountain cedar) and shows some cross-reactivity with Cry j 1 (Japanese cedar). It has only limited cross-reactivity with ragweed and mugwort pectate lyases.

This matters when you are trying to figure out which pollen is the primary driver versus which sensitizations are just echoes from cross-reactive proteins. Cup a 1 testing helps separate genuine cypress sensitization from a pattern that originated with a related tree.

Tracking Your Trend Over Time

A single Cup a 1 IgE result tells you whether you are sensitized right now. What it cannot tell you is whether your sensitization is rising, holding steady, or fading. That trajectory matters, especially if you are starting allergen immunotherapy, changing where you live, or noticing symptoms shifting season to season.

Get a baseline before symptoms peak, then retest in 6 to 12 months if you are pursuing immunotherapy or making major exposure changes. Annual checks during stable periods are reasonable. Comparing your own results over time is more informative than comparing your number to anyone else's, because the absolute IgE level varies between people for reasons that have nothing to do with how badly you react.

What to Do With an Unexpected Result

If your Cup a 1 IgE is positive and your symptoms match the cypress pollen season in your region, the next conversation worth having is about whether allergen-specific immunotherapy makes sense. Molecular component testing including Cup a 1 changed immunotherapy prescriptions in about half of polysensitized patients in one Catalan study, lifting the share of patients receiving targeted treatment compared with the standard workup alone.

If your result is positive but your symptoms do not match the cypress season, talk to an allergist about ordering related pollen components and food allergen panels, particularly for Pru p 7 if you have had reactions to peach or other fruits. If your result is negative but symptoms persist, the workup should expand to other regional aeroallergens, including dust mite, grass, olive, and animal dander components. A negative Cup a 1 does not mean you have no allergy. It means cypress is not the engine.

When Results Can Be Misleading

Allergen-specific IgE tests are generally stable from day to day, but a few things are worth knowing. Cross-reactive carbohydrate determinants (sugar molecules shared across many plant proteins) can occasionally produce positive IgE readings that do not match real-world symptoms. Skin prick tests done in the prior days do not affect a blood IgE result, but recent dosing of biologic drugs that suppress IgE could theoretically reduce circulating allergen-specific IgE.

A positive IgE means sensitization, not necessarily clinical allergy. Some people make IgE to cypress without ever developing symptoms. The lab number is one input. Your symptoms during cypress season are the other. Both are needed.

What Moves This Biomarker

Evidence-backed interventions that affect your Cypress (Cup a 1) IgE level

↑ Increase
Living in a region with high cypress pollen exposure
Where you live shapes whether you develop cypress sensitization in the first place. In a French multicenter cohort, the odds of being sensitized to Cup a 1 were about seven times higher in Montpellier, a high cypress pollen city, than in Paris. Sensitization rates in Italian and Asian cohorts also tracked closely with local airborne cypress counts.
LifestyleStrong Evidence
↓ Decrease
Allergen-specific immunotherapy guided by molecular component testing
When molecular testing including Cup a 1 was added to standard workup in polysensitized patients, allergen-specific immunotherapy prescriptions changed in about half of cases, and the share of patients receiving immunotherapy rose substantially. Targeted immunotherapy is the only treatment shown to modify the underlying allergic sensitization rather than just suppress symptoms. Direct evidence that immunotherapy lowers Cup a 1 IgE specifically over time was not reported in the studies reviewed.
MedicationModerate Evidence
↓ Decrease
Anti-IgE biologic therapy with omalizumab
Omalizumab, an injectable antibody that binds and removes free IgE, improved symptoms of seasonal allergic rhinitis driven by Japanese cedar and cypress pollen in an observational clinical-practice study, even when started after peak pollen dispersal. The drug lowers the pool of circulating free IgE available to trigger reactions. The studies reviewed did not specifically report changes in Cup a 1 IgE measurements during treatment.
MedicationModerate Evidence

Frequently Asked Questions

References

14 studies
  1. Siroux V, Lupinek C, Resch Y, Curin M, Just J, Keil T, Kiss R, Lodrup Carlsen KC, Melen E, Nadif R, Pin I, Skrindo I, Vrtala S, Wickman M, Anto J, Valenta R, Bousquet JThe Journal of Allergy and Clinical Immunology2017
  2. Tanaka J, Fukutomi Y, Shiraishi Y, Kitahara a, Oguma T, Hamada Y, Watai K, Nagai T, Taniguchi M, Asano KAllergology International2021
  3. Hwang Y, Motomura C, Fukuda H, Kishikawa R, Watanabe N, Yoshihara SPeerj2022
  4. Garriga-baraut T, Moncin MS, Tena M, Labrador-horrillo MClinical and Translational Allergy2023
  5. Quan P, Sabate-bresco M, D'amelio C, Pascal M, Garcia B, Gastaminza G, Blanca-lopez N, Alvarado MI, Fernandez FJ, Moya C, Bartra J, Ferrer M, Goikoetxea MJAnnals of Allergy, Asthma & Immunology2021